{
    "clinical_study": {
        "@rank": "136210", 
        "arm_group": [
            {
                "arm_group_label": "Buparid; Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Buparid 1mg budesonide/2 ml nebulizer solution"
            }, 
            {
                "arm_group_label": "Budes; Treatment B", 
                "arm_group_type": "Active Comparator", 
                "description": "Budes Nasal Spray 50 \u00b5g budesonide/pump"
            }
        ], 
        "brief_summary": {
            "textblock": "The study should create data for the selection of a clinically relevant endpoint to assess\n      the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic\n      Rhinosinusitis."
        }, 
        "brief_title": "Buparid/PARI SINUS Versus Budes\u00ae Nasal Spray in the Therapy of Chronic Rhinosinusitis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rhinosinusitis", 
        "condition_browse": {
            "mesh_term": "Sinusitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with confirmed diagnosis of chronic rhinosinusitis\n\n          -  Patient without alternative other than sinus surgery\n\n          -  Patient's written informed consent obtained prior to any screening or study-specific\n             procedure\n\n          -  Male or female, \u2265 18 years of age\n\n          -  Patient is able to undergo nasal therapy without restrictions\n\n          -  Capable to correctly use the PARI SINUS device\n\n          -  Capable of understanding the purpose and risk of the clinical trial\n\n          -  Female patients with childbearing potential must have a negative urine pregnancy test\n             prior to first IMP administration.\n\n          -  Patient is able to participate in the study according to Investigator's opinion\n\n        Exclusion Criteria:\n\n          -  Patients with cystic fibrosis\n\n          -  Patients with polyposis nasi grade I-IV\n\n          -  Patients with prior FESS (Functional Endoscopic Sinus Surgery)\n\n          -  Patients with demonstrated allergies against aeroallergens\n\n          -  Pregnant or breastfeeding women\n\n          -  Any active invasive bacterial, viral or fungal infection within one week prior to\n             first investigational medicinal product (IMP) administration\n\n          -  No clinically relevant abnormal parameters of vital signs, blood biochemistry or\n             renal/hepatic function\n\n          -  Unlikely to comply with visits, inhalation procedures or other measurements scheduled\n             in the protocol\n\n          -  Receipt of an investigational drug as part of a clinical trial within 4 weeks prior\n             to first administration of IMP\n\n          -  Any co-existing medical condition that in the Investigator's judgement will\n             substantially increase the risk associated with the patient's participation in the\n             clinical trial\n\n          -  Psychiatric disorders or altered mental status precluding understanding of the\n             informed consent process and/or completion of the necessary procedures\n\n          -  Drug or alcohol abuse\n\n          -  End-stage malignancies\n\n          -  Known hypersensitivity to Budesonide\n\n          -  Patients with topical or oral steroid therapy within the last 3 months\n\n          -  Patients needing > 1 mg/day Budesonide (or steroidal equivalent) for therapy of\n             asthma\n\n          -  Patients on therapy with intranasal steroids, leukotriene-receptor antagonists,\n             decongestants, antihistamines or antibiotics\n\n          -  Patients with frequent epistaxis (> 1 episode per week)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955980", 
            "org_study_id": "12082.102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Buparid; Treatment A", 
                "description": "Inhalation", 
                "intervention_name": "Budesonide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Budes; Treatment B", 
                "description": "Nasal Spray", 
                "intervention_name": "Budesonide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CRS", 
            "without polyposis"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "martin.canis@med.uni-goettingen.de", 
                    "last_name": "Martin Canis, MD", 
                    "phone": "+49 551 39", 
                    "phone_ext": "22801"
                }, 
                "facility": {
                    "address": {
                        "city": "Goettingen", 
                        "country": "Germany", 
                        "zip": "37099"
                    }, 
                    "name": "University Goettingen"
                }, 
                "investigator": {
                    "last_name": "Martin Canis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sven.becker@med.uni-muenchen.de", 
                    "last_name": "Sven Becker, MD", 
                    "phone": "+49 89 7095", 
                    "phone_ext": "0"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "University Munich"
                }, 
                "investigator": {
                    "last_name": "Sven Becker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes\u00ae Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis", 
        "overall_contact": {
            "email": "s.prante@pari.de", 
            "last_name": "Stefanie Prante", 
            "phone": "+49 89 742846", 
            "phone_ext": "830"
        }, 
        "overall_contact_backup": {
            "email": "g.boerner@pari.de", 
            "last_name": "Gerhard Boerner", 
            "phone": "+49 89 742846", 
            "phone_ext": "59"
        }, 
        "overall_official": {
            "affiliation": "University Goettingen", 
            "last_name": "Martin Canis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to surgery", 
            "measure": "Avoidance or postponing of sinus surgery", 
            "safety_issue": "No", 
            "time_frame": "From baseline  to week 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessments will be done using the Sino-Nasal outcome Test 22 (SNOT 22)", 
                "measure": "Changes in Health-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 48"
            }, 
            {
                "description": "Rhinomanometry", 
                "measure": "Nasal obstruction", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Determination of the thickness of the mucosa using Magnetic Resonance Imaging", 
                "measure": "Inflammation of the nasal mucosa and paranasal sinus", 
                "safety_issue": "No", 
                "time_frame": "Changes from Baseline at Week 8"
            }, 
            {
                "description": "Treatment-emergent adverse events", 
                "measure": "Safety assessment", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "Pari Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pari Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}